KURA ONCOLOGY INC. -

Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit

25 11 2024 07:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

20 11 2024 17:00:00 提供 Nasdaq GlobeNewswire

Kura Oncology Reports Third Quarter 2024 Financial Results

07 11 2024 16:05:01 提供 Nasdaq GlobeNewswire

Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting

05 11 2024 09:09:54 提供 Nasdaq GlobeNewswire

Kura Oncology to Report Third Quarter 2024 Financial Results

31 10 2024 07:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)

24 10 2024 07:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors

23 10 2024 07:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology

30 9 2024 18:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors

17 9 2024 07:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology to Participate in Cantor Global Healthcare Conference

10 9 2024 07:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology Reports Second Quarter 2024 Financial Results

08 8 2024 16:05:00 提供 Nasdaq GlobeNewswire

Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST)

08 8 2024 07:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology to Report Second Quarter 2024 Financial Results

01 8 2024 07:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 7 2024 07:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes

24 6 2024 07:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 6 2024 07:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology to Participate in Jefferies Global Healthcare Conference

29 5 2024 07:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML

14 5 2024 07:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

08 5 2024 07:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 5 2024 07:30:00 提供 Nasdaq GlobeNewswire